0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV59.68%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.48Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Allogene Therapeutics Stock Discussion
07/11/2024 - 23:00
Phase 1 TRAVERSE Trial Demonstrated a Single Infusion of ALLO-316 Can Yield an Overall Response Rate of 50% and Confirmed Response Rate of 33% in Patients with CD70 Tumor Proportion Score (TPS) of Greater than 50%
TRAVERSE Trial Highlights the Ability of CD70 Dagger® Te...
3.20+
No comment yet